Phaeochromocytomas are uncommon tumours of adrenal or extra-adrenal chromaffin tissue. About 2-26% of these have been reported to metastasize, but, on histological criteria, it is virtually impossible to predict malignant behaviour of the tumour. Using immunohistochemistry, we analysed the protein expression of SNAIL, a zinc-finger transcription factor, in a series of 50 phaeochromocytoma specimens from 42 patients. We found that SNAIL-expressing cells are frequent in metastatic primary tumours and their metastases, whereas in tumours without metastases, SNAIL expression is commonly absent. We conclude that the expression of SNAIL may be of use in predicting the metastatic potential of phaeochromocytoma.
Introduction
Phaeochromocytoma is a rare tumour of the adrenal medulla. We lack exact incidence figures in Finland, but in Sweden, the incidence is 2.1 per million (Stenstrom & Svardsudd 1986) . It usually arises from adrenergic cells in the adrenal medulla. Extra-adrenal phaeochromocytomas arising from the paraganglion system are called paragangliomas. They represent w15-20% of all phaeochromocytomas (Lenders et al. 2005) . Paragangliomas seem to be more aggressive and associated with malignant potential than phaeochromocytomas. Additionally, paragangliomas produce excessive amounts of noradrenaline, while phaeochromocytomas may produce just noradrenaline (i.e. von Hippel-Lindau tumours) or a combination of adrenaline and noradrenaline with distinct clinical manifestations.
Most phaeochromocytomas are non-metastatic. However, even local phaeochromocytomas may be symptomatic due to high catecholamine secretion, leading to high blood pressure, pallor, flushing and constipation. From 2.4 to 26% of all, phaeochromocytomas are metastatic ( Melicow 1977 , Proye et al. 1992 ).
The 5-year survival of non-metastatic tumours is O95%, but that of metastatic tumours only 44% (Salmenkivi et al. 2004) . Owing to the risk of metastases, patients are followed up for a long time by monitoring catecholamine levels and flush symptoms. Positron emission tomography has been used to detect metastases (Timmers et al. 2007 , Jager et al. 2008 , but this technology is not in use in our centre. Another means of predicting the metastatic behaviour of the tumour would be of clinical value.
As many endocrine tumours, phaeochromocytomas lack reliable histological features that distinguish benign (i.e. non-metastatic) from malignant (i.e. metastatic) tumours (Salmenkivi et al. 2003) , with perhaps the exception of extracapsular or intravascular growth and/or necrosis that are usually found in metastatic phaeochromocytomas (Salmenkivi et al. 2004) . Classical histopathological features of malignancy like hyperchromasia and pleomorphism are useless, as they are frequently seen in phaeochromocytomas with either metastatic or non-metastatic behaviour (Salmenkivi et al. 2003 (Salmenkivi et al. , 2004 . Malignant behaviour can currently only be defined by the appearance of the metastases. Extra-adrenal phaeochromocytomas are reported to be malignant more often than adrenal phaeochromocytomas, whereas phaeochromocytomas found in the familiar bilateral form of the disease or as a manifestation of multiple endocrine neoplasia are equally malignant as sporadic phaeochromocytomas (John et al. 1999) .
The zinc-finger transcription factor SNAIL is often overexpressed in metastatic carcinoma and melanoma (Poser et al. 2001 , Blanco et al. 2002 . By binding to E-box sequences in the promotor regions of several genes, it downregulates E-cadherin, claudin and occludin expression (Moreno-Bueno et al. 2008) . These are key components of adherence/tight junctions of cells. SNAIL also regulates the expression of genes controlling cell motility, proliferation and differentiation (Prindull & Zipori 2004 , Klymkowsky & Savagner 2009 . SNAIL also promotes epithelialmesenchymal transition and cell invasion (Oda et al. 1994 , Oku et al. 2006 . However, it is also a key regulator of neural crest migration, thus regulating the migration of chromaffin cells during the formation of the adrenal glands and paraganglionic system (Le Douarin et al. 1994) , which links SNAIL to phaeochromocytomas and paragangliomas.
We have now analysed, by immunohistochemistry, 50 samples from 42 patients with phaeochromocytoma for their expression of SNAIL, a transcription factor essential for the migration of the neural crest. Our data show that high frequency of SNAIL-expressing cells is unambiguously associated with the metastatic phaeochromocytomas. Furthermore, SNAIL is lacking in a majority of non-metastatic phaeochromocytomas. Our data suggest that evaluation of SNAIL expression in phaeochromocytoma can be used to identify the group of patients that need to be followed intensely due to an enhanced risk for metastases.
Materials and methods

Tumour material
We collected a series of phaeochromocytoma surgical samples of both adrenal (nZ48) and extra-adrenal (nZ2) origin. The 50 surgical samples are from 42 individuals treated at the Department of Surgery, Helsinki University Central Hospital, which is a referral centre for endocrine surgery during . The material, including clinical records, was collected retrospectively during the year 2009. Data were obtained from the hospital records and from the Population Registry of Finland and Statistics Finland. The clinical diagnosis was non-metastatic phaeochromocytoma in 32 patients and metastatic phaeochromocytoma in 10 patients, including two patients with paraganglioma. From four individuals with a metastatic disease, tissue from both the primary tumour and metastases was available. Four patients developed a recurrence of the disease, and samples of the recurrent tumour were included in the material.
Four samples of normal adrenal medullary tissue were obtained from individuals who underwent adrenalectomy for unrelated reasons.
All samples underwent routine histopathological diagnostics during the time of treatment. This was performed by pathologists specialised in endocrine pathology (i.e. the authors K Salmenkivi, J Arola, P Heikkilä). Furthermore, all samples were re-evaluated for this study by K Salmenkivi and grouped according to previously published criteria as non-metastatic either (A) without or (B) with histological suspicious features or (C) malignant (Salmenkivi et al. 2003) . Malignancy was defined as histologically or radiologically proven metastatic disease during or after the surgery of the primary tumour. All the malignant phaeochromocytomas presented at least one histologically suspicious feature. Table 1 describes the demographic features of all patients included in the study: the size of the tumour; patient age at diagnosis; biochemical profile; side of tumour; location of distant metastases; time to metastasis (months) following operation of primary tumour; follow-up time of patients (months), which ones are alive and dead; the causes of death and the SNAIL expression score of primary tumour are tabulated. The mean and median follow-up times are both 99 months.
Immunohistochemistry
Sections of formalin-fixed, paraffin embedded tumour biopsies were stained with SNAIL antibody. Epitope retrieval was performed by pretreatment in a microwave oven for 7 min in a 10 mM sodium citrate buffer (pH 6.0). The rabbit polyclonal SNAIL antibody (1:600 dilution, catalogue # ab17732, AbCam plc. Cambridge, UK) was diluted in Powervision antibody blocking solution (Immunovision Technologies & Co., Burlingame, CA, USA) and incubated for 60 min at 21 8C. Binding of the primary antibody was detected with a PowervisionCPoly-HRP histostaining kit (Immunovision Technologies & Co.). Tissue sections were counterstained with haematoxylin.
The immunostainings were scored blinded to the clinical diagnosis; first independently by two of the authors (H Sariola and V Häyry) and then jointly V Hä yry et al.: SNAIL in metastatic phaeochromocytoma www.endocrinology-journals.org Table 1 The demographic profile of the patients included . This method of scoring was selected after analysis of SNAIL in a test series of nine tumours, before the whole material was analysed and before subsequent statistical analyses. Tissue sections of normal adult adrenal glands were used as negative controls and biopsies of breast carcinoma as a positive control for SNAIL expression in each staining set. Additional controls included were omittance of primary antibody and inclusion of normal rabbit IgG (Zymed Laboratories Inc. San Francisco, CA, USA) as mock.
Microscopy
For photography, a Nikon Eclipse 80i microscope with a Nikon Plan Fluor 60! objective, Nikon DS-Fi1 digital camera and NIS-Elements F imaging software version 2.3 were used (Nikon Corporation, Tokyo, Japan).
Statistical analysis
For categorical, non-ordered variables, cross tabulations were analysed using the c 2 test; when the c 2 test could not be used, the Fisher's exact test was chosen. All P values are two sided. SPSS version 12.0.1 software (SPSS, Chicago, IL, USA) was used for all statistical analyses. Sensitivity and specificity values were calculated as previously described (Altman & Bland 1994) .
Ethical considerations
The project has been approved by the ethical committee of Helsinki University Central Hospital, and all work has been done in accordance with the Helsinki declaration.
Results
SNAIL expression is high in metastatic phaeochromocytomas
In the normal adrenal medulla, no SNAIL expression was detected (Fig. 1) . Likewise, in 18 out of 32 specimens representing 32 cases of non-metastatic phaeochromocytomas, no SNAIL expression was seen. In 13 out of 32 specimens of non-metastatic tumours, SNAIL-positive tumour cells were observed at low or Metnef, 24 h urinary metanephrine (mmol); Normet, 24 h urinary normetanephrine (mmol); MOMA, 24 h urinary 3-methoxy-4-hydromandelic acid (mmol).
V Hä yry et al.: SNAIL in metastatic phaeochromocytoma
www.endocrinology-journals.org moderate frequency and only in one specimens the expression was high (Table 2 ). This patient was treated during 2007, and thus long-term clinical follow-up data are not yet available for this individual. Out of 14 tumour specimens representing 10 cases with metastases, 12 showed high or intermediate SNAIL expression and only 2 out of 14 showed low expression. None of the metastatic tumours were SNAIL negative (Table 2) .
In all samples from which tissue from both the primary tumour and its metastases was available, intermediate or high SNAIL expression was seen in both the primary tumour and the metastasis (Fig. 1,  Table 2 ).
The difference in SNAIL expression in specimens of non-metastatic versus metastatic tumours was statistically highly significant (Fisher's exact test P!0.001).
Also when considering the patients rather than specimens, another statistical analysis was performed. Because in some patients more than one sample was available (i.e. recurrence, metastasis), so we used only the primary tumour specimen as basis of calculations. Also the two cases with paragangliomas were excluded, because of their dissimilar clinical behaviour compared with adrenal tumours. SNAIL expression correlated with metastatic behaviour (Fisher's exact test P!0.001).
SNAIL protein expression level was also compared with the clinical parameters presented in Table 1 . No statistically significant correlations were observed.
Finally, the sensitivities and specificities of the diagnostic value of SNAIL expression were calculated to distinguish between malignant (metastatic) and benign (non-metastatic) tumour behaviour in all Endocrine-Related Cancer (2009) 16 1211-1218 www.endocrinology-journals.org excluded recurrent tumours and paragangliomas in the calculations. By setting the cut-off between nonimmunoreactivity and any level of immunoreactivity, SNAIL expression had a 100% sensitivity of detecting the malignant tumours. However, by this method, the specificity was only 56%. If the cut-off level was set at 70% or more immunoreactive tumour cell nuclei, the sensitivity was 50%, but the specificity was 97% to detect metastatic disease.
For the group of tumours (B) with suspicious histological features (local invasive growth through the capsule or into blood vessels and/or necrosis), the frequency of SNAIL-positive samples was higher (50%) than in the group of non-metastatic tumours without aggressive histology (A) (40%), but less than in metastatic tumours (C) (100%). SNAIL protein expression correlated significantly with invasive growth seen in the histopathological material (Fisher's exact test PZ0.006).
Discussion
Several histochemical and molecular markers (MIB-1, Cd34, VEGF, hTERT; p53, bcl-2 and c-erbB-2) have been investigated to identify the metastatic subgroup of phaeochromocytoma (de Krijger et al. 1999 , van der Harst et al. 2000 , Favier et al. 2002 , Boltze et al. 2003 , but the results have been inconclusive. Ohta et al. (2005) has investigated, with real-time quantitative PCR, the RNA expression of 11 genes in phaeochromocytoma. Six of these were downregulated in malignant versus benign tumours. One of these was E-cadherin, a downstream target of SNAIL. We could not confirm this on protein level. In our material, only 12 out of 50 samples expressed the E-cadherin protein, and even these only marginally (data not shown). Compared with other genes studied by Ohta et al. the relative E-cadherin RNA expression was two log-orders lower, which may relate to our own negative finding on protein level. SNAIL, a zinc-finger transcription factor, was first discovered in Drosophila, where it regulates the dorsoventral patterning. In flies without Snail, the ventral organs fail to develop (Boulay et al. 1987 , Kasai et al. 1992 . The adrenal medulla emerges from neural crest. When the neural crest delaminates from neural tube, its cells start to migrate and proliferate (Le Douarin et al. 1994 , Tucker 2004 ). The transcription factor SNAIL is one of the proteins that altogether make the specific molecular signature for migrating crest cells. The expression of SNAIL is first seen at the beginning of neural crest migration, it is maintained during migration, continues throughout the process of adrenal gland formation and is turned off in the mature adrenal medulla (Le Douarin et al. 1994 , Tucker 2004 .
The transcription factor SNAIL is also involved in epithelial-mesenchymal transition in tumour cells, suppressing, for instance, E-cadherin expression. (Batlle et al. 2000 , Cano et al. 2000 . High SNAIL expression incurs a mesenchymal, fibroblastic phenotype to tumour cells, in which epithelial cell adhesions are suppressed (De Craene et al. 2005) . SNAIL expression is elevated in several malignancies of epithelial origin, e.g. oral squamous cell carcinoma and breast carcinoma (Blanco et al. 2002 , Usami et al. 2008 .
We now show that a high frequency of SNAILexpressing tumour cells in primary phaeochromocytomas suggests metastatic potential. SNAIL expression detects with high sensitivity metastatic disease. Likewise, lack of SNAIL expression is a characteristic of non-metastatic tumours. High and diffuse SNAIL expression in phaeochromocytomas with metastases (frequency O70% positive nuclei) suggests that SNAIL expression can be used for identification of patients at high risk of metastases requiring intense clinical follow-up. Thus, the data indicate that the majority of patients with SNAILnegative phaeochromocytoma may be followed up less intensely than those tumours with SNAIL expression. Two of these were paragangliomas and the remaining 12 specimens represent eight patients with four recurrent diseases.
V Hä yry et al.: SNAIL in metastatic phaeochromocytoma
www.endocrinology-journals.org SNAIL expression thus detects or confirms malignancy in metastatic lesions, but, in primary tumours, moderate or high SNAIL expression may be considered predictive for metastasis. It is also noteworthy that during follow-up (median 99 months), none of the SNAIL-negative cases developed metastases or recurrence.
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